Cosmo N.V. today announced that it will change its ticker symbol on the SIX Swiss Stock Exchange from “COPN” to “CMHC”. This change is expected to take effect at the opening of trading on Monday, August 17, 2026.
Cosmo N.V. (“Cosmo”), a global leader in AI-driven healthcare and specialty pharmaceuticals, today reported financial results for the first half of 2026. During the period, the Company delivered double-digit growth in recurring revenues, advanced its dermatology pipeline toward regulatory submission, further strengthened the GI Genius™ platform with next-generation commercial and technological capabilities, and maintained a strong financial position. Cosmo ended the reporting period debt-free, with more than €205 million in cash, cash equivalents and investments, and reaffirms its full-year 2026 financial guidance.
Cosmo N.V. (“Cosmo”) announced today that it will publish its Half-Year 2026 results on Thursday, 23 July 2026 at 7:00 am CEST.
Cosmo N.V. (“Cosmo”) is pleased to announce the launch of its innovative acne cream Winlevi® (clascoterone 1% cream) in Austria and Germany by its commercial partner InfectoPharm Arzneimittel und Consilium GmbH (“InfectoPharm”). Winlevi® is available in both countries since June 1. Cosmo is the exclusive manufacturer of the product.
Cosmo N.V. (“Cosmo”) is pleased to make known that its commercial partner Glenmark Specialty S.A (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd., today announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in adolescents limited to facial application) by the European Commission to Cassiopea S.p.A., a subsidiary of Cosmo N.V., in October 2025.
Cosmo N.V. (“Cosmo” or “the Company”) today announced the completion of patient enrolment in its Phase II clinical trial (EUCT number: 2023-506917-23-00) evaluating its novel investigational therapy, Rifamycin enema, for the treatment of distal ulcerative colitis (UC) and ulcerative proctitis. A total of 77 patients were enrolled at 24 clinical sites in Europe, reflecting strong investigator engagement and efficient study execution.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced positive 12-month Phase III results for Clascoterone 5% topical solution in men with mild-to-moderate androgenetic alopecia (AGA), reinforcing the product’s potential to redefine treatment in one of the largest and most underserved categories in dermatology. The data confirm three critical attributes physicians and patients have been waiting for: long-term safety, continued efficacy with ongoing use, and a novel mechanism designed to target the underlying biology of hair loss.
Cosmo Pharmaceuticals N.V. announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting (AGM). A total of 10,354,065 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 59.02% of the total outstanding ordinary shares in the share capital of Cosmo as of the record date.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced its participation at NVIDIA GTC 2026, the world’s leading conference for artificial intelligence (AI) and accelerated computing, taking place in San Jose (CA), USA, from March 16 to March 19.
Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce the convening of its upcoming Ordinary Annual General Meeting of Shareholders (AGM) to be held on 10 April 2026 in Amsterdam.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today reports its audited financial results for the fiscal year ended December 31, 2025. The Company also publishes its 2025 Annual Report and ESG Report 2025, available on its corporate website under www.cosmohealthconfidence.com/key-financial-reports.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett’s esophagus. The collaboration represents an important step in expanding the clinical scope of Cosmo’s GI Genius™ platform beyond colorectal cancer screening into upper gastrointestinal (GI) indications.
Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce its participation in the following upcoming investor conferences:
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund.
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced today that it will publish its Full-Year 2025 results on Monday, 9 March 2026 at 7:00 am CET.
Cosmo Pharmaceuticals N.V. (“Cosmo”) reports strong preliminary unaudited 2025 revenue and year end cash, reflecting continued revenue growth and a robust cash position. Cosmo will publish its 2025 audited consolidated financial statements as well as the Annual and ESG Reports 2025 on March 9, 2026.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced compelling topline results from its two pivotal Phase III trials of clascoterone 5% topical solution for male androgenetic alopecia (AGA, also known as male-pattern hair loss), marking a potential first major therapeutic breakthrough in hair-loss treatment in more than three decades.
Cosmo Pharmaceuticals N.V., a global leader in AI-driven healthcare and dermatology innovations, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgaris in patients aged twelve years and older. This milestone marks another key step in Cosmo’s mission to build health confidence worldwide, expanding access to its first-in-class topical anti-androgen to one of the largest dermatology markets in Latin America. With approval already granted in the Mexican market, availability of Winlevi® extends to over 50% of the Latin American population.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced two major milestones in its sustainability journey, underscoring its commitment to transparency, responsible operations, and ESG leadership.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced that it will participate in the following upcoming healthcare investor conferences:
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced that ColonPRO EU, the Company’s next-generation artificial intelligence software for colonoscopy, has received CE certification. Following FDA clearance in the United States, this certification brings to Europe the most advanced AI-assisted colonoscopy platform ever developed. The system has already been used to support more than four million procedures worldwide.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced that the European Commission has granted regulatory approval in the EU for Winlevi® (clascoterone 1% cream) for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years, with usage in adolescents limited to facial application. This formal approval came following on the positive recommendation for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on 25th of August 2025. Cosmo is already working at full speed with its commercial partners to prepare for launch across 20 European markets.
Cosmo Pharmaceuticals N.V., a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgaris in patients aged twelve years and older. This approval marks another important milestone in Cosmo’s global dermatology expansion and reinforces the Company’s commitment to delivering innovative, patient-centric therapies.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending European approval of Winlevi® (clascoterone 1% cream) for the treatment of facial acne vulgaris in both adults and adolescents aged 12 to <18 years. The decision follows a successful re-examination of the initial negative CHMP opinion issued in April.
Cosmo Pharmaceuticals N.V., a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its multi-year manufacturing and supply agreement with Takeda (TSE:4502/NYSE:TAK), to produce Mesalazine MMX 1200 mg (marketed as Lialda® in the USA and as Mezavant in Europe) oral, once-daily treatment for ulcerative colitis, reinforcing its position as a trusted partner for global production of key medicines.
Cosmo Pharmaceuticals N.V. (“Cosmo”) notes the recent market volatility following reports on potential U.S. tariffs on Swiss pharmaceutical companies.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today reported strong half-year results for 2025, underscoring the Company’s strategic execution, commercial momentum, and capital discipline across its key growth platforms.
Cosmo Pharmaceuticals N.V., a global leader in AI-driven healthcare and specialty pharmaceuticals, is pleased to announce the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its first entry into Southeast Asia through the partnership with Hyphens Pharma International Limited (“Hyphens Pharma”). Winlevi® is a topical treatment for acne vulgaris in patients aged twelve years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions.
Cosmo Pharmaceuticals N.V., a global leader in AI-powered healthcare and specialty pharma, today announced a major leap forward in its sustainability journey, underscoring its ambition to lead the next decade of healthcare innovation with purpose, transparency, and impact.
Cosmo N.V., a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced its vision through 2030, along with a bold strategic plan, during its Investor Day event in Zurich.
Cosmo today announced the signing of an agreement to sell “Digital Trust” to its existing customer Tinexta InfoCert, Europe’s largest Certification Authority and a subsidiary of Tinexta S.p.A., a publicly listed company in Italy. The transaction is expected to close by the end of June 2025 and will generate €8.3 million in revenue for Cosmo.
Cosmo Pharmaceuticals N.V. today announced that in July 2025, it will initiate their first usability study of a medical device software application connecting the Medtronic GI Genius™ intelligent endoscopy module, an AI-powered platform for gastrointestinal endoscopy, with Apple Vision Pro. The study, to be conducted at Rush University Medical Center in Chicago under the leadership of Irving Waxman, MD, James R. Lowenstine Professor and Chief, Division of Digestive Diseases & Nutrition, will evaluate the real-time use of this innovative technology during live colonoscopy procedures.
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting. A total of 9,135,061 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 52.07% of the total outstanding ordinary shares in the share capital of Cosmo as of the record date.
Cosmo is attending this year’s Digestive Disease Week® (DDW), held in San Diego, California from May 3-6, where its leadership team is advancing a focused agenda of strategic meetings with key opinion leaders (KOLs), innovators, and potential partners in AI and gastrointestinal (GI) drug development.
Cosmo is excited to announce that Endovision Limited, a leading innovator in endoscopic imaging solutions, has received EU MDR certification for Cerebro, a Real-Time AI-powered guide for complete Esophagogastroduodenoscopy (EGD) procedures. As one of the first Computer-Assisted Quality (CAQ) tools for endoscopy, Cerebro marks a significant step forward in transforming procedures by elevating inspection quality, standardizing protocols, and ultimately enhancing patient outcomes. Cerebro software is intended to be distributed later this year via the AI Access™ platform integrated into the Medtronic GI Genius™ intelligent endoscopy system, which is manufactured by Cosmo.
Cosmo Pharmaceuticals N.V. (“Cosmo” or the “Company”) today announced the convening of its Annual General Meeting 2025 to be held on Friday 30 May 2025, at 12:00 CEST, at Strawinskyhuis, Prinses Amaliaplein 3, 1077 XS Amsterdam, the Netherlands. The agenda includes, inter alia, the following discussion and voting items:
Following the recent CHMP opinion regarding the marketing authorization application for Winlevi® (clascoterone cream 1%) in Europe, Cosmo Pharmaceuticals N.V. confirms that its financial guidance for 2025 remains unchanged.
Cosmo Pharmaceuticals N.V. announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on the marketing authorization application (MAA) for Winlevi® (clascoterone cream 1%) for the treatment of acne vulgaris.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team.
Cosmo Pharmaceuticals N.V. (“Cosmo”) has published today its Annual Report for the fiscal year ending December 31, 2024. As already outlined in the unaudited 2024 Full-Year results on March 6, 2025, the reporting year was characterized by strong financial performance, exceptional revenue growth, significant strategic advancements, and a clear roadmap for future sustained corporate developments.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today reported its unaudited results for the fiscal year ending December 31, 2024. The consolidated and audited 2024 Full-Year results along with the 2024 Annual Report and ESG Report will be published on March 21, 2025.
Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce that it will host an Investor Day on Wednesday, April 9, 2025.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo’s commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team.
Cosmo Pharmaceuticals N.V. (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a global research-led pharmaceutical company, today announced that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi® in the United Kingdom. Winlevi® is a topical treatment for acne vulgaris in patients aged 12 years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions.
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced today that it will publish its unaudited Full-Year 2024 results on Thursday, 6 March 2025 at 7:00 am CET.
Cosmo Pharmaceuticals N.V. (“Cosmo”) reports strong preliminary unaudited 2024 revenue and year end cash, reflecting exceptional revenue growth and a solid cash position. Cosmo will publish 2024 audited consolidated financial statements and Annual Report 2024 on March 20, 2025.
Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce the appointment of Dominika Spilarova as its Chief Strategy Officer, effective January 10, 2025. This newly created role within Cosmo’s leadership team highlights the company’s focus on strategy-led growth and innovation. She will be reporting to the CEO.
Cosmo shareholders today approved the proposal by the Board of Directors to appoint Deloitte Accountants B.V. as new independent auditor of the Company for the financial year ending on 31 December 2024.
Cosmo Pharmaceuticals N.V. (“Cosmo”) is delighted to announce the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016.
Cosmo Pharmaceuticals N.V. (“Cosmo”) is excited to announce the appointment of Ms. Egle Gedrimaite, as the new Head of Global Business Development, effective October 1, 2024. Egle Gedrimaite will report to Giovanni Di Napoli, CEO of Cosmo. With extensive experience in expanding global business operations and driving strategic market growth, Egle is a valuable addition to Cosmo’s management team, as the Company continues its ambitious expansion plans.
Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (“Cosmo”), the developer and manufacturer of the GI Genius™ intelligent endoscopy system, is pleased to announce the publication of a study in “The Lancet”. This study, titled “Polyp detection with colonoscopy assisted by the GI Genius™ artificial intelligence endoscopy module compared with standard colonoscopy in routine colonoscopy practice (COLO-DETECT): a multicentre, open-label, parallel-arm, randomised controlled trial”, represents a significant advancement in colorectal cancer screening and detection.
Cosmo Intelligent Medical Devices, a division of Cosmo Pharmaceuticals N.V. (“Cosmo”) focused on pioneering medical devices powered by Artificial Intelligence, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the next generation GI Genius™ hardware, the latest development of the GI Genius™ intelligent endoscopy system, which Medtronic exclusively distributes globally. This milestone reaffirms the GI Genius™ platform’s leadership in AI-enhanced endoscopy and marks a significant advancement in the realm of medical technology.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced its 2024 half year results.
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced today that it will publish its Half-Year 2024 results on Wednesday, 24 July 2024 at 07:00 am CEST.
Cosmo shareholders today approved all resolutions proposed by the Board of Directors at an Extraordinary General Meeting of the Company. A total of 7,173,931 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders constituting 40.89% of the total outstanding ordinary shares in the share capital of Cosmo as of the record date.
Cosmo Pharmaceuticals N.V. (“Cosmo”) reported that its partner and exclusive licensee of Lumeblue® (Methylene Blue MMX®) for China, China Medical System Holdings Limited (“CMS”) (SEHK: 867), has received the approval for the innovative product in the territory by the National Medical Products Administration of China (NMPA) on 11 June. Today, on 18 June, CMS also obtained the corresponding Drug Registration Certificate. Cosmo will be the exclusive supplier for the product.
Cosmo Pharmaceuticals N.V. (“Cosmo”) with its Cosmo Intelligent Medical Devices division (“Cosmo IMD”) is consolidating its strategy to accelerate the adoption of responsible and regulated AI in healthcare, obtaining pragmatic results in its mission to address unmet clinical needs and improve patient outcomes.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced its final audited results for the financial year 2023.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that its shareholders approved all agenda items at today’s annual general meeting of shareholders.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024.
Cosmo Pharmaceuticals N.V. (“Cosmo”) announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system developed by Cosmo IMD, along with a new strategic collaboration designed to enhance patient care.
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced its preliminary unaudited results for the financial year 2023.
Cosmo Pharmaceuticals N.V. (“Cosmo”) reported today that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (“Sun Pharma”) has announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi® (clascoterone cream 1%). Winlevi® is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Cosmo Pharmaceuticals N.V. (“Cosmo”) announced today that it will publish its Full-Year 2023 results on Wednesday, 20 March 2024 at 7:00 am CET.
